Eculizumab in paroxysmal nocturnal haemoglobinuria

被引：8

作者：

Charneski, Lisa ^{[1
]}

Patel, Priti N. ^{[2
]}

机构：

[1] Univ Maryland, Dept Pharm Practice & Sci, Rockville, MD 20850 USA

[2] St Johns Univ, Dept Clin Pharm Practice, New York, NY USA

来源：

DRUGS | 2008年 / 68卷 / 10期

关键词：

D O I：

10.2165/00003495-200868100-00001

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Eculizumab is a monoclonal antibody that binds with high affinity to the complement protein C5, preventing terminal complement-mediated intravascular haemolysis in patients with paroxysmal nocturnal haemoglobinuria (PNH). In three well designed clinical trials in patients with PNH, eculizumab blocked serum haemolytic activity and decreased transfusion rates. Pooled data from the three clinical trials demonstrated that eculizumab treatment decreased the overall thromboembolism rate in patients with PNH. Eculizumab carries a black box warning for the potential increased risk of meningococcal infections and requires patients to receive the meningococcal vaccine at least 2 weeks before starting treatment. Eculizumab is the first drug to be approved by the US FDA for the treatment of PNH and is a novel treatment that offers a new option for patients with PNH.

引用

页码：1341 / 1346

页数：6

共 50 条

[1] Eculizumab in paroxysmal nocturnal haemoglobinuria
Escudero-Jimenez, Angel
Jesus Esteban-Mensua, Maria
Lopez-Briz, Eduardo
Jarque-Ramos, Isidro
Borrell-Garcia, Carmela
Luis Poveda-Andres, Jose
[J]. EJHP PRACTICE, 2011, 17 (01): : 31 - 35
[2] Eculizumab for paroxysmal nocturnal haemoglobinuria
Parker, Charles
[J]. LANCET, 2009, 373 (9665): : 759 - 767
[3] Eculizumab in Paroxysmal Nocturnal Haemoglobinuria
Lisa Charneski
Priti N. Patel
[J]. Drugs, 2008, 68 : 1341 - 1346
[4] With paroxysmal nocturnal haemoglobinuria and treatment with eculizumab
Tomas Algado, Jose
Luque, Rafael
Nunez, Ramiro
Sanchez, Berta
[J]. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2012, 30 (02): : 109 - 110
[5] Eculizumab A Review of its Use in Paroxysmal Nocturnal Haemoglobinuria
McKeage, Kate
[J]. DRUGS, 2011, 71 (17) : 2327 - 2345
[6] Antiphospholipid antibodies in patients with paroxysmal nocturnal haemoglobinuria receiving eculizumab
Darnige, Luc
de Latour, Regis Peffault
Zemori, Laurence
Socie, Gerard
Fischer, Anne-Marie
Helley, Dominique
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2011, 153 (06) : 789 - 791
[7] Complement assessment in patients with paroxysmal nocturnal haemoglobinuria treated by eculizumab
de Latour, R. Peffault
Fremeaux-Bacchi, V.
Porcher, R.
Rodriguez-Otero, P.
Abbes, S.
Roncelin, S.
Socie, G.
[J]. BONE MARROW TRANSPLANTATION, 2013, 48 : S414 - S415
[8] Management of paroxysmal nocturnal haemoglobinuria in the eculizumab era: the bedside and beyond
Risitano, A.
Marando, L.
Hill, A.
Ranaldi, D.
Seneca, E.
Serio, B.
Ricci, P.
Selleri, C.
Gianfaldoni, G.
Mannelli, F.
Milano, F.
Amendola, A.
Boschetti, C.
Di Bona, E.
Bonfigli, S.
Barbano, F.
Rodeghiero, F.
Zanella, A.
Iori, A.
Notaro, R.
Rother, R.
Kroon, H.
Hillmen, P.
Luzzatto, L.
Rotoli, B.
[J]. BONE MARROW TRANSPLANTATION, 2008, 41 : S142 - S142
[9] The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab
Kelly, Richard
Arnold, Louise
Richards, Stephen
Hill, Anita
Bomken, Charlotte
Hanley, John
Loughney, Andrew
Beauchamp, Jon
Khursigara, Gus
Rother, Russell P.
Chalmers, Elizabeth
Fyfe, Andrew
Fitzsimons, Edward
Nakamura, Ryotaro
Gaya, Anna
Risitano, Antonio M.
Schubert, Joerg
Norfolk, Derek
Simpson, Nigel
Hillmen, Peter
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 (03) : 446 - 450
[10] Successful pregnancy outcome in paroxysmal nocturnal haemoglobinuria on long term eculizumab
Kelly, R. J.
Arnold, L. M.
Richards, S. J.
Hill, A.
Bomken, C.
Hanley, J.
Loughney, A.
Beauchamp, J.
Khursigara, G.
Rother, R. P.
Chalmers, E.
Fyfe, A.
Fitzsimons, E.
Nakamura, R.
Gaya, A.
Rotoli, B.
Risitano, A.
Schubert, J.
Hillmen, P.
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2009, 145 : 23 - 23

← 1 2 3 4 5 →